Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease

Ren H., Elliott N., Lye B., Sharif Shohan MU., Cross J., Field L., Ponnusamy K., Rice S., Jackson T., Leontari I., Ouazzani NE., Thomas R., Inglott S., Bartram J., Smith O., Bond J., Roberts IAG., Halsey C., Bashford-Rogers R., Milne T., Roy A., Karadimitris A.

DOI

10.1101/2025.01.22.633541

Type

Preprint

Publication Date

2025-01-01T00:00:00+00:00

Permalink More information Close